{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.54","upperLimit":"0.90","value":"0.75"},{"groupId":"OG001","lowerLimit":"0.32","upperLimit":"0.73","value":"0.53"},{"groupId":"OG002","lowerLimit":"0.24","upperLimit":"0.66","value":"0.44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"description":"CBR is defined as the proportion of participants who reached stable disease, partical response and complete resposne during treatment based on RECIST 1.1","dispersionType":"90% Confidence Interval","groups":[{"description":"* Participants will receive eribulin intravenously on Day 1 and Day 8\n* Pembrolizumab is administered intravenously Day 1, on a 21-day cycle\n\nEribulin: The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).\n\nPembrolizumab: The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.","id":"OG000","title":"Liposarcomas"},{"description":"* Participants will receive eribulin intravenously on Day 1 and Day 8\n* Pembrolizumab is administered intravenously Day 1, on a 21-day cycle\n\nEribulin: The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).\n\nPembrolizumab: The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.","id":"OG001","title":"Leiomyosarcomas"},{"description":"* Participants will receive eribulin intravenously on Day 1 and Day 8\n* Pembrolizumab is administered intravenously Day 1, on a 21-day cycle\n\nEribulin: The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).\n\nPembrolizumab: The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.","id":"OG002","title":"Undifferentiated Pleomorphic Sarcomas"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Clinical Benefit Response Rate (CBR)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}